Processa (PCSA) Amended Form 4 Shows 26,339-Share Sale, 8,335 Indirectly Owned

Rhea-AI Filing Summary

Wendy Guy, identified as the reporting person and listed as Chief Administrative Officer, submitted an amended Form 4 for Processa Pharmaceuticals, Inc. (PCSA). The filing states a transaction date of 07/24/2025 and records a disposition of 26,339 shares of the issuer's common stock (transaction code V). After the reported transaction the filing shows beneficial ownership of 8,335 shares held indirectly through CorLyst, LLC.

The amendment expressly notes it was filed to retract a prior Form 4 that was filed in error. The amended Form 4 is signed via power of attorney on behalf of Wendy Guy by John J. Wolfel and dated 09/18/2025.

Positive

• Amendment filed to retract prior error, improving accuracy of public insider reporting
• Clear disclosure of post-transaction indirect ownership (8,335 shares via CorLyst, LLC)

Negative

• Original Form 4 contained an error requiring an amendment
• No price or proceeds information provided, limiting assessment of financial impact

Insights

Securities/Corporate Governance Analyst

TL;DR: Amendment corrects an earlier filing and discloses a sale of 26,339 shares with remaining indirect ownership of 8,335 shares via CorLyst, LLC.

The amendment is a routine corrective disclosure that restores accuracy to Section 16 reporting. The key investor-impact facts are explicit: a reported disposition of 26,339 shares on 07/24/2025 and an indicated post-transaction indirect holding of 8,335 shares. The filing also documents use of a power of attorney for signature, which is common in Form 4 practice. There is no additional financial data, price information, or explanation of the original error included in the filing.

Securities Compliance Specialist

TL;DR: The amended Form 4 corrects prior reporting; it is a compliance-driven amendment rather than new economic disclosure.

From a compliance standpoint, the amendment satisfies the requirement to correct the public record by explicitly stating the retraction of the prior Form 4. The form lists the reporting person's relationship to the issuer and records the non-derivative disposition (Code V). The filing does not provide transaction price or other contextual details, limiting assessment of economic impact. The filing appears procedural and does not on its face introduce new material operational or financial information about the issuer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Guy Wendy

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								26,339	D
Common Stock								8,335	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the amended Form 4 for PCSA disclose?

The filing discloses a disposition of 26,339 shares on 07/24/2025 and post-transaction indirect beneficial ownership of 8,335 shares via CorLyst, LLC.

Why was the Form 4 amended?

The amendment states it was filed to retract the prior Form 4, which was filed in error.

Who is the reporting person on the Form 4/A for PCSA?

The reporting person is Wendy Guy, listed as Chief Administrative Officer of Processa Pharmaceuticals, Inc.

When was the transaction dated in the amended Form 4?

The transaction date reported in the form is 07/24/2025.

Does the Form 4/A include the sale price or proceeds?

No. The amended Form 4 does not provide any price or proceeds information for the reported disposition.